Picard Medical, Inc. announces successful completion of the first in vivo implantations of the fully implantable Emperor Total Artificial Heart (TAH).
The Emperor TAH demonstrated stable blood circulation, efficient energy usage, and performance mirroring a natural human heart.
The positive outcomes of the implantations mark a significant advancement in total artificial heart technology.
Milestone Achievement
The successful implantations signify a major advancement in total artificial heart technology and validate Picard Medical's leadership in this field.
Technological Progress
The Emperor TAH displayed stable hemodynamics, physiologic preload sensitivity, and afterload independence, reflecting natural heart behavior.
Market Expansion
The Emperor platform aims to broaden the total artificial heart market through improved performance, energy efficiency, and patient usability.
- The completion of the in vivo implantations showcases the Emperor platform's potential as a fully implantable alternative to heart transplantation.
- Successful implantations in pre-clinical models highlight the device's ability to provide stable blood circulation and mimic natural heart functions.
- The positive performance characteristics observed in acute experiments support the accelerated development of the Emperor platform towards enhancing patients' quality of life.
Picard Medical's successful in vivo implantations of the Emperor Total Artificial Heart mark a significant milestone in total artificial heart technology. The positive outcomes pave the way for further advancements and solidify Picard's position as a pioneer in artificial heart innovation.